Navigation Links
Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer
Date:2/14/2013

Wednesday, February 13, 2013, Cleveland: Cleveland Clinic researchers have found that colorectal cancer outcomes could be improved with regular genetic screening for Lynch syndrome, the most common hereditary, adult-onset cause of colorectal cancer, as published in the online version of the Journal of Clinical Oncology.

Lynch syndrome is the most common genetic cause of colon cancer in adults. The study found that a universal screening program of all colorectal cancers surgically removed at Cleveland Clinic resulted in increased identification of Lynch syndrome patients by successfully referring individuals whose tumors screen positive to genetics professionals. Identification of Lynch syndrome will lead to significantly improved outcomes for colorectal cancer patients and their family members.

Most colorectal cancers are sporadic, and are not due to inherited genetic causes. More than 140 million Americans are diagnosed with colorectal cancer each year. With one out of 35 colorectal cancer cases resulting from Lynch syndrome, a hereditary condition that predisposes to a wide variety of cancers at earlier ages, a clinical recommendation was established in 2009 to screen all colorectal patients for Lynch syndrome. With four million Americans having Lynch syndrome each year, and most going unrecognized, a systematic manner of screening for this condition presented a challenge. Furthermore, another challenge is ensuring that all individuals whose tumors screen positive for potential Lynch syndrome are referred to genetics professionals.

By identifying Lynch syndrome patients, measures can be taken to thwart the development of additional cancers in the patient, as well as increase surveillance in the patient. Once Lynch syndrome has been identified in a patient, his/her family members can be referred to genetics professionals to determine if they too have inherited the same condition. As patients who carry the Lynch gene un
'/>"/>

Contact: Laura Ambro
ambrol@ccf.org
216-636-5876
Cleveland Clinic
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
2. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
3. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
4. New clinical trial explores novel noninvasive colon cancer screening test
5. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
6. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
7. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
8. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
9. AAO-HNS releases updated Clinical Indicators
10. Sequencing works in clinical setting to help -- finally -- get a diagnosis
11. VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), ... general the State of Washington,s Department ... new enrollment and central issuance system for driver,s licenses and ... The project planning and development will start in January 2015, ...
(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... known as marine protected areas provide many direct benefits ... zones appear to offer limited help to corals in ... study. To protect coral reefs from climate change, ... that can meaningfully reduce greenhouse gas emissions, researchers said. ...
...  AnaptysBio, Inc., a privately held therapeutic antibody company, today ... Michael Gallatin, Ph.D. to the company,s Therapeutic Advisory Board ... members of AnaptysBio,s TAB, Jan de Vries, Ph.D. and ... http://photos.prnewswire.com/prnh/20111205/SF16052LOGO ) AnaptysBio,s TAB is constituted to ...
... and Stanford University are expanding EteRNA a unique research ... that are then tested in a laboratory thanks to ... additions already implemented is a new puzzle in which players ... the presence of other molecules. , A $1 million grant ...
Cached Biology News:Rising ocean temperatures harm protected coral reefs 2Rising ocean temperatures harm protected coral reefs 3AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board 2AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board 3AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board 4Keck award enables Carnegie Mellon and Stanford to dramatically expand crowdsourced RNA design 2
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... San Francisco, CA (PRWEB) February 27, 2015 ... is joining forces on February 28 with patients and ... to raise awareness for Rare Disease Day®. Rare ... rare diseases and calling attention to the special challenges ... community around them. , “Cytokinetics is proud to stand ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015  23andMe, the ... Kate Black as Privacy Officer and Corporate ... and state privacy laws as well as health care ... team, she will be responsible for reviewing, updating and ... in the U.S. and abroad. She joined the company ...
(Date:2/26/2015)... Fla. , Feb. 26, 2015 DuPont ... growth priorities driven by key research advancements and product ... at today,s Bank of America Merrill Lynch 2015 Global ... the challenge of building grain supplies the last two ... continue at the pace of the last decade, when ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... China, Oct. 27 /Xinhua-PRNewswire/ -- Recently, China ... State Intellectual,Property Office for two patents for ... Materials and Industrialized Production,Method of Fully Biodegradable ... patent applications have both obtained acceptance numbers,200810064592 ...
... Oct. 27 Trubion Pharmaceuticals Inc.,(Nasdaq: ... a Phase 1/2a study,demonstrating that repeat administration ... significant improvements in rheumatoid arthritis,(RA) signs and ... (ACR),criteria. Trubion also announced positive results following ...
... Biosciences, Inc. ("Carna"),announced on October 27, 2008, the ... Company ("SUBC"). Under the terms of this,Agreement, SUBC ... within China., With China,s emergence as a ... biopharmaceutical companies have now established,research and production facilities ...
Cached Biology Technology:Patent Technologies Keep CGMT in a Leading Position in the Industry 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company 2
...
PURA Immunogen: PURA (NP_005850, 183 a.a. ~ 293 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: